Protagenic Therapeutics, Inc.\new (PTIX) Return on equity 2022–2026
Protagenic Therapeutics, Inc.\new (PTIX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
52.2%FY2026 · since FY2022: -45.5% → 52.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | 52.2% | — |
| FY2024 | -136.3% | -84.9 pp |
| FY2023 | -51.4% | -5.9 pp |
| FY2022 | -45.5% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice